Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI

• Published in: Anticancer research 2011-05, Vol.31 (5), p.1777-1782
• Main Authors: OCVIRK, Janja, REBERSEK, Martina, BOC, Marko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Biological and medical sciences; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Capecitabine; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease Progression; Female; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Fluorouracil - therapeutic use; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Leucovorin - therapeutic use; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Male; Medical sciences; Middle Aged; Neoplasm Staging; Retrospective Studies; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Survival Rate; Treatment Outcome; Tumors; Vascular Endothelial Growth Factor A - antagonists & inhibitors
• ISSN: 0250-7005; 1791-7530

The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer. However, clinical data for capecitabine and irinotecan (XELIRI) with bevacizumab are limited. A retrospective study was conducted on 139 patients with metastatic colorectal cancer to assess the efficacy and safety of first-line bevacizumab in combination with XELIRI or FOLFIRI. Primary endpoints were overall response rate (ORR), disease control rate and radical resection rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. No significant differences in efficacy were observed between patients administered XELIRI or FOLFIRI with bevacizumab. The ORR, median OS and PFS and recorded adverse events (AEs) were comparable to those previously reported, with no new or unexpected AEs observed. Bevacizumab is similarly efficacious and well tolerated when administered with XELIRI or FOLFIRI.